The biopharmaceutical company Xention Ltd, based in Cambridge, UK, recently announced the positive results yielding from its phase 1 trial of the drug XEN-DO103, administered orally for the treatment of atrial fibrillation (AF) and protection against AF.  Researchers note that the trial was conducted in the UK and sought to assess single and multiple ascending oral doses of XEN-DO103 in healthy study participants. The study was designed to evaluate the safety and pharmacokinetics of various doses and the effects of food. 

The results indicate that the drug was well tolerated and researchers observed no significant food, gender, or age related effects. The study also indicates that a detailed electrocardiogram (ECG) assessment of data collected from the 30 healthy study participants suggested that the drug had no effect on the QTcF interval.

Tim Brears, chief executive officer of Xention, rearticulates the trial’s findings and adds that, “The potential market for XEN-DO103 is significant with one in four adults over the age of 40 developing AF in their lifetimes and approximately 3 million patients suffering atrial-fibrillation-related strokes each year.” Brears also reports that the company is preparing for a phase 2 efficacy trial of the drug. 

Source: Xention Ltd